132 results about "Rectal carcinoma" patented technology

The present application belongs to the technical field of ostomy base plate, and particularly relates to a leakage-proof ostomy base plate for postoperative colorectal cancer, which comprises a suction cup, the upper side wall of the suction cup is fixedly connected with a connecting cylinder, the outer wall of the connecting cylinder is fixedly sleeved with two limiting rings matched with an ostomy bag, the outer wall of the suction cup is fixedly sleeved with an adhesive layer, the inner wall of the connecting cylinder is fixedly connected with an elastic film, and a center hole is formed in the center position of the elastic film. Before the ostomy base plate is used, the size and shape of the center hole of the ostomy base plate can be freely adjusted according to the use condition, so that the leakage risk of excrement caused by the size deviation of the manually cut traditional fixed circular center hole is avoided, the compression damage of the ostomy mucosa caused by the too small cutting is eliminated, the sealing property of the base plate and the skin around the ostomy is improved, the complications such as fecal dermatitis are reduced, the nursing operation difficulty is reduced, and the wearing comfort and the life quality of the patient are improved.

This invention relates to a method for detecting colorectal cancer tumor cell-associated microorganisms, specifically a method for eliminating intestinal fecal microbial contamination and detecting colorectal cancer tumor-associated microorganisms, belonging to the field of biotechnology. This invention initially eliminates fecal microbial contamination from the sample structure by coarsely shearing and enzymatically digesting the intestinal folds and villi; then, it uses a 40μm cell sieve to filter out incompletely digested tissue fragments, further eliminating intestinal fecal bacteria contamination, and collecting a single-cell suspension; subsequently, the collected single-cell suspension is repeatedly washed with 300g centrifugation to remove as many intercellular or loosely bound "transient bacteria" as possible, retaining intracellular and firmly colonized microorganisms. Ultimately, this eliminates the severe contamination from the large and complex fecal microorganisms, allowing the detection of tumor cell-associated microorganisms, which are already present in low biomass. This method is suitable for detecting microorganisms in gastrointestinal tissues that are in direct contact with the environment.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

This invention relates to an intelligent decision support system for rectal cancer prognosis integrating digital pathological images, belonging to the field of medical image processing technology. The system includes a data acquisition module for collecting multiple sets of sample data; a feature selection module for identifying multiple key medical imaging features of rectal cancer based on the multiple sets of sample data; a model building module for acquiring a pre-trained deep learning model and constructing a rectal cancer prognosis prediction model based on transfer learning, the pre-trained deep learning model, the multiple sets of sample data, and the multiple key medical imaging features of rectal cancer; an image acquisition module for acquiring pre- and post-operative medical images of the rectal cancer patient to be evaluated; and a recurrence prediction module for predicting the recurrence probability of the rectal cancer patient to be evaluated based on the pre- and post-operative medical images of the patient using the rectal cancer prognosis prediction model. This system has the advantage of improving the accuracy of non-invasive prediction of postoperative recurrence of rectal cancer.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The disclosure relates to means and methods in the treatment of a subject having a colorectal cancer. The disclosure in particular relates to therapeutic uses and methods involving a bispecific antibody that binds EGFR and cMET. Such bispecific antibody is particularly useful in the treatment of metastatic colorectal cancer or a locally advanced, unresectable colorectal cancer. The disclosure further relates to uses in such methods and to the use in the manufacture of a medicament for the treatment of such cancers.

This invention discloses an engineered CAR-T cell targeting HIF-1α and its application in tumor immunotherapy. The CAR-T cell expresses a chimeric antigen receptor regulated by the hypoxia-responsive element HRE promoter, with its extracellular domain specifically binding to HIF-1α and its intracellular domain employing the 4-1BB+CD3ζ signaling module. Simultaneously, through immune checkpoint knockout and cytokine / chemokine modification, it achieves hypoxia-dependent activation, anti-exhaustion, high infiltration, and strong killing effects. The CAR-T cells of this invention significantly improve the adaptability to the solid tumor microenvironment and therapeutic efficacy, reduce off-target toxicity, and can be used to prepare drugs for treating malignant tumors such as lung cancer, liver cancer, pancreatic cancer, colorectal cancer, and glioblastoma, possessing significant clinical translational value.

This invention relates to a novel compound derived from nutmeg and an anticancer composition comprising the same. The present invention isolates several novel compounds derived from nutmeg extract and confirms that most of these novel compounds exhibit cytotoxic activity against various cancer cell lines. Five compounds (3, 4, 6, 9, and 11) were identified as having high cytotoxic activity against gastric and colorectal cancers. In particular, the compound represented by chemical formula 3 was confirmed to not only effectively induce apoptosis by regulating the cell cycle of cancer cells but also effectively inhibit tumor growth in xenograft mouse models, thus making it an effective anticancer composition.

The present invention relates to the field of oncology. In particular, the present invention relates to biomarkers for colorectal cancer and their use for diagnosing or staging colorectal cancer. The biomarkers of the present invention allow for the sensitive and accurate diagnosis of colorectal cancer and the differentiation between non-metastatic and metastatic colorectal cancer.

This disclosure particularly relates to combination therapy of oncolytic adenoviruses with topoisomerase I inhibitors or their prodrugs (such as topotecan or SN-38) or prodrugs of topoisomerase inhibitors (such as irinotecan) for the treatment or prevention of ovarian cancer, cervical cancer, lung cancer, colon or colorectal cancer and / or pancreatic cancer.

The application discloses a primer probe combination for detecting methylation of two sites of colorectal cancer and a kit thereof. The primer probe combination is a primer probe combination for detecting methylation of a cg08392199 site of a LIFR gene and a primer probe combination for detecting methylation of a cg13096260 site of a SDC2 gene; the methylation of the cg08392199 site of the LIFR gene and the cg13096260 site of the SDC2 gene is correlated with colorectal cancer. The kit comprises the primer probe combination. The application adopts combined detection of the two sites of SDC2 and LIFR for the first time, has innovation, and the sensitivity of combined detection of the two sites in the detection of colorectal cancer reaches 92%, and the specificity is as high as 100%, thereby providing a primer probe combination for early screening of colorectal cancer with high sensitivity and high specificity and a kit.

The application discloses a tumor intervention target and application thereof, and the tumor intervention target is a C9ORF50 gene, and a gene sequence of the C9ORF50 gene is shown as SEQ ID NO. 1. The application firstly finds that down-regulation of C9ORF50 gene expression is used for treating colorectal cancer, liver cancer, pancreatic cancer, breast cancer and melanoma, and has advantages of targetability, good treatment effect and the like.

This invention discloses 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives, their synthesis methods and applications, belonging to the field of pharmaceutical technology, and involving two series of compounds: 3-sulfonamido-2'-hydroxy-4,4',6'-trimethoxychalcone and 8,3'-disulfonamido-5,7,4'-trimethoxyflavanone, and their preparation methods. Starting with 2-hydroxy-4,6-dimethoxyacetophenone and p-anisaldehyde or 4-methoxy-3-nitrobenzaldehyde, 2'-hydroxy-4,4',6'-trimethoxychalcone or 3-amino-2'-hydroxy-4,4',6'-trimethoxychalcone intermediates were synthesized via the Claisen-Schmidt reaction. Then, through sulfonation and intramolecular Michael addition reactions, 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives were synthesized. The preparation method is simple, mild, and yields high results. In vitro and in vivo activity tests show that the derivatives disclosed in this invention have significant in vitro inhibitory activity against gastric cancer, esophageal cancer, colorectal cancer, and lung cancer cell lines, acting as inhibitors of the protein YBX1 / RPN1. Clinically, they can be applied to targeted therapy for cancers such as gastric cancer, esophageal cancer, colorectal cancer, and lung cancer.

The application discloses a kind of SNPs loaded engineered escherichia coli dual-response delivery systems and its preparation method and application, the preparation method includes the engineered escherichia coli of overexpressing Flt3L and TIM-3 scFv is co-incubated with NHS-PEG-CHO, obtain aldehyde functionalized escherichia coli;After activation SNPs is reacted with TFA-hydrazine, obtain hydrazine functionalized SNPs;Aldehyde functionalized escherichia coli and hydrazine functionalized SNPs are reacted;The delivery system of the application can rely on SNPs under laser stimulation Photo-thermal effect, photodynamic effect and generate a large number of ROS, efficiently induce tumor cells to occur immunogenic cell death (ICD), and by overexpressing Flt3L and TIM-3 scFv, activate DC cell and block TIM-3 path, restore DC, T cell function, realize the efficient synergy of photodynamic therapy+photothermal therapy+immunotherapy, and then reach the effective treatment of colorectal cancer.

The application discloses application of a pharmaceutical composition taking GL-V9 and a chemotherapeutic drug as active ingredients in treatment of tumors. When GL-V9 is combined with a classical chemotherapeutic drug to treat tumors, a drug synergistic effect can be obviously achieved, and the effect is obviously superior to combination of similar drugs and the chemotherapeutic drug. The chemotherapeutic drugs include 5-fluorouracil; and the tumor types include leukemia, colorectal cancer and lung cancer.

This invention relates to the field of biotechnology, and in particular to a primer-probe combination for detecting methylation sites in cancer and its applications. This invention is the first to discover that abnormal methylation at specific sites of the TRIB3 gene is significantly associated with the occurrence and development of colorectal cancer, and abnormal methylation at specific sites of the MAPT gene is significantly associated with the occurrence and development of gastric cancer. This correlation has not been publicly reported in the prior art, possessing novelty and significant clinical application value. The primer-probe combination provided by this invention is used to detect the methylation status of the TRIB3 gene or the MAPT gene in a sample. Specifically, when the primer-probe combination is used to detect the methylation level at specific sites of the TRIB3 gene, it can be used for the auxiliary diagnosis, early screening, or risk assessment of colorectal cancer; when the primer-probe combination is used to detect the methylation level at specific sites of the MAPT gene, it can be used for the auxiliary diagnosis, early screening, or risk assessment of gastric cancer.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

The application discloses a method for predicting biological age based on enteroscopy pictures, and belongs to the field of digestive endoscopy image analysis. The method first screens enteroscopy pictures without abnormalities, and completes quality control and edge cutting; then constructs an image package with multiple pictures in a single report, extracts features and weighted aggregation by using a multi-instance learning model based on attention; and converts age prediction into a classification task and introduces a Gaussian soft label to realize high-precision biological age prediction. The application can mine aging-related features from enteroscopy images without obvious abnormalities, does not need additional equipment and invasive operation, has strong generalization, and can be used for risk stratification of enteroscopy-negative people and precise prevention and treatment of colorectal cancer.

Provided are a pharmaceutical composition for treating colorectal cancer and use thereof. Active ingredients of the pharmaceutical composition comprise: polyethylene glycol modified IL-2 and capecitabine. The pharmaceutical composition shows a very good therapeutic effect in an animal model of colorectal cancer. The effect is remarkably superior to that of a single drug, and thus the pharmaceutical composition has a good application prospect.

The invention relates to the technical field of molecular biology and precision medical treatment, and relates to a molecular marker for predicting FOLFOX chemosensitivity and application thereof. A patient-derived colorectal cancer organoid biological sample library is constructed, the heterogeneity of in-vitro drug reaction is analyzed and evaluated through transcriptome, clinical groups sensitive to FOLFOX chemotherapy can be accurately recognized, a molecular marker prediction system containing 11 genes is obtained through further screening, and the molecular marker prediction system is used for predicting the FOLFOX chemotherapy. The method effectively overcomes the technical defect of lack of accurate prediction of colorectal cancer chemosensitivity at present, and has important value in the aspects of revealing disease mechanisms and guiding personalized treatment.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.

This invention discloses the application of the biomarker PLXNC1 in the diagnosis, treatment, and prognosis prediction of colorectal cancer. The biomarker PLXNC1 has good diagnostic efficacy for colorectal cancer, with high accuracy, sensitivity, and specificity. Furthermore, this invention experimentally verifies for the first time that reagents that inhibit PLXNC1 expression levels can significantly inhibit the proliferation, migration, and invasion of colorectal cancer cells, indicating that the biomarker PLXNC1 described in this invention can be applied to the diagnosis, treatment, and prognosis prediction of colorectal cancer and has good clinical application value.

This invention belongs to the field of novel pharmaceutical uses, and more specifically, relates to the application of ethyl acetate extract of turmeric in the preparation of drugs for treating colorectal cancer. The preparation method of the extract is as follows: turmeric slices are soaked overnight in 15 times their weight of a 70% (v / v) ethanol solution, refluxed at 85°C three times, 2 hours each time. The extracts are combined and concentrated until no alcohol odor remains. The extract is then dried to constant weight to obtain the total extract. The total extract is reconstituted with water and extracted three times with ethyl acetate at an equal volume ratio. The extracts are combined and dried to constant weight to obtain the final product. Experimental results show that this extract is particularly effective in improving disease activity index, restoring colon length, reducing tumor number, and alleviating histopathological damage, and has no significant toxicity to major organs. This extract can be formulated into oral or injectable preparations, providing a new natural drug candidate for the treatment of colorectal cancer.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

This invention discloses Lactobacillus plantarum ( Lactobacillus plants The application of Lactobacillus plantarum AY01 in the preparation of products inhibiting colorectal cancer liver metastasis is described. The Lactobacillus plantarum AY01 is deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC M 20221517. The advantages of this invention are: Lactobacillus plantarum AY01 has the characteristics of inhibiting CT26.WT cell viability, suppressing CT26.WT cell clone formation, inhibiting CT26.WT cell scratch repair, reducing its migration ability, and thus reducing tumor metastatic potential. Mouse experiments with colorectal cancer liver metastasis show that the bacterial suspension of this strain can significantly reduce the number of tumors at metastatic sites in the liver, inhibit liver tumor colonization and proliferation, reduce inflammatory cell infiltration, reduce the proportion of Ki-67 and PCNA positive cells in the liver, alleviate liver tissue damage caused by colorectal cancer liver metastasis, promote the restoration of normal liver structure, protect the liver, and exert an anti-colorectal cancer liver metastasis effect, providing theoretical support for probiotic adjuvant therapy for colorectal cancer liver metastasis.

The disclosure relates to methods, compositions, and kits for detecting and analyzing surface marker displaying agents (SMDAs). The disclosure further relates to methods for detecting, diagnosing, monitoring response to treatment or recurrence, or predicting overall survival, progression-free survival or duration of response in a subject suspected of having colorectal cancer (CRC) comprising performing one or more assays on at least one biological sample from the subject to detect one or more specific populations of EVs.

The application discloses a 3'-deoxyadenosine compound and application thereof in preparation of an antitumor drug. The 3'-deoxyadenosine compound and the pharmaceutical composition thereof have good antitumor proliferation effect. Compared with a parent drug, the 3'-deoxyadenosine compound has better affinity to a cell membrane, so that the half-life of in-vivo metabolism of the drug is longer, and the drug stays in the body for a longer time. Compared with other nucleoside antitumor drugs, the cordycepin derivative and the pharmaceutical composition thereof have a wider range of tumor types and effects, including excellent inhibition effect on gastric cancer, pancreatic cancer, liver cancer, small cell lung cancer, colorectal cancer, melanoma, ovarian cancer and the like, and the side effect is lower and the curative effect is better.

The application discloses application of FBXO2 in colorectal cancer and prognosis judgment. Specifically, the application finds the role of FBXO2-FABP5 axis in p53-mediated colorectal cancer ferroptosis resistance: p53-activated FBXO2 promotes lysosomal degradation of FABP5 through the CMA pathway, leading to a decrease in PUFA levels, and ultimately leading to colorectal cancer ferroptosis resistance. Therefore, FBXO2 protein and FABP5 can be used as new colorectal cancer diagnostic markers.